Harvard Health: The new Alzheimer’s blood test: What it means for diagnosis

Posted on August 24, 2026 by michelleclarke2015
The new Alzheimer’s blood test: What it means for diagnosisA gloved hand holds a vial of blood in front of an array of MRI scan images.


The ability to diagnose Alzheimer’s disease simply and cost-effectively took a major step forward in May 2025, when the FDA approved the first blood test for early detection of the condition. It’s intended for people ages 55 or older with signs or symptoms of the disease.The test, called Lumipulse, isn’t the only one of its kind to look for Alzheimer’s blood markers. But it’s the only one that has made it through the challenging regulatory approval process, a milestone that’s considered a game changer.



Get your copy of Alzheimer’s DiseaseAlzheimer's Disease

Have you noticed memory problems piling up in ways that affect daily life in yourself or someone you love? Do you find yourself struggling to follow a conversation or find the right word, becoming confused in new places, or botching tasks that once came easily?

More than 5 million Americans have Alzheimer’s disease, and estimates suggest it will affect 13.8 million by 2050. Already, it is the sixth leading cause of death in the United States. This Special Health Report, Alzheimer’s Disease: A guide to coping, treatment, and caregiving, includes in-depth information on diagnosing Alzheimer’s and treating its symptoms. 

SHOW ME MORE →

To find out about the significance of this development and what this could mean for Alzheimer’s diagnosis, we turned to Dr. Andrew Budson, lecturer in neurology at Harvard Medical School and chief of Cognitive and Behavioral Neurology at VA Boston Healthcare System.

Q. Why is Lumipulse being watched so closely when doctors already can order similar blood tests for patients?

Dr. Budson: A number of accurate Alzheimer’s blood tests are available for clinical use, and some blood tests have been marketed directly to consumers. But without FDA approval, FDA safety regulation, and public and private insurance coverage, the tests have not been part of the standard of care for diagnosis – they’ve just been novel tests that people could pay for out of their own pocket. For example, testing might cost between $300 and $1,750 at some companies. Financial assistance is sometimes available. Instead, we’ve relied on two other, more complicated, invasive, and costly types of FDA-approved tests that are covered by insurance to confirm the presence of Alzheimer’s: a positron emission tomography (PET) scan of the brain and a lumbar puncture, or “spinal tap,” which can detect disease biomarkers in a sample of fluid surrounding the brain and spinal cord.

Q. How does the FDA approval of Lumipulse change things?

Dr. Budson: The approval means that the blood test has been evaluated by scientists, is doing what it claims, and has the potential to be beneficial in people’s care.The next step is for insurance to consider covering it, particularly Medicare and Medicaid. If that happens, which is expected soon, the test will likely become the standard of care. We’ll have a pathway for the rapid detection of Alzheimer’s, which will allow us to start treatment immediately.

Q. How does Lumipulse work?

Dr. Budson: The test analyzes a blood sample to look for several proteins that are characteristic of Alzheimer’s disease. It calculates the ratio of amyloid-beta 40 (which is naturally present in the brain and considered normal) to amyloid-beta 42 (which is involved in forming Alzheimer’s brain plaques). The test also looks for a type of tau protein (phosphorylated tau 217) that causes tangles in brain cells.About 80% of the time, the blood test is either highly positive or highly negative, a result that’s accurate more than 90% of the time. About 20% of the time, the test is inconclusive.

Q. How might you and other physicians use Lumipulse, if it’s covered by insurance?

Dr. Budson: Here is the scenario I envision: The primary care provider identifies a patient with memory complaints and cognitive impairment as determined by a sensitive but brief cognitive screening test. The patient has blood tests to look for vitamin deficiencies and thyroid disorders and an MRI scan to look for brain tumors, fluid collections, and other structural problems. If the blood tests and the MRI do not provide answers, the doctor then orders the approved blood test to look for Alzheimer’s markers.

Q. In that scenario, how are the blood test results used?

Dr. Budson: If the blood test is clearly negative, the patient is told the reassuring news, but also told that their memory problems will be readdressed in six months.

If something is still clearly wrong, the patient is referred to a memory specialist to look for other causes of dementia. If the test is inconclusive, the patient is referred to a memory specialist for either an amyloid PET scan or a lumbar puncture to determine the correct diagnosis .If the blood test comes back positive, the patient is referred to a neurologist or another specialist for treatment with an amyloid-targeting therapy – donanemab (Kisunla) or lecanemab (Leqembi). These medicines remove amyloid plaques from the brain, hopefully before too much damage is done. It’s not a cure, but it slows the disease process. And studies show that the earlier you intervene with treatment for someone with symptomatic Alzheimer’s in early stages, the more effective the medications will be.

Q. Do you anticipate that other blood tests for Alzheimer’s will be approved?

Dr. Budson: Yes, I expect several other tests will quickly gain FDA approval. Because we have disease-modifying treatments for Alzheimer’s disease, there is now an imperative to detect and treat our patients quickly. Just like in a patient in whom cancer is detected, the treatment doesn’t need to be initiated in a week, but six months is too long, and treatment would ideally begin within two months. Blood-based biomarkers will be crucial to help make this scenario into a reality.For more information on Alzheimer’s disease—check out this special health report, Alzheimer’s Disease: A guide to coping, treatment and caregiving, from Havard Health Publishing.Image: © Andrew Brookes/Getty ImagesShare this story:Share on FacebookShare on XAlzheimer's Disease: A guide to diagnosis, treatment, and caregivingFEATURED CONTENTAlzheimer’s Disease
•What is Alzheimer’s disease?•Recognizing the symptoms•Risk factors for Alzheimer’s disease•Special Section: 5 healthy habits that reduce risk•Is it Alzheimer’s or another dementia?•Diagnosing Alzheimer’s disease•Medications for Alzheimer’s disease
Click here to learn more »You are currently subscribed to HEALTHbeat as michellemarcella.clarke1@gmail.com.

UPDATE EMAIL FREQUENCY/PROFILE
UNSUBSCRIBE
SUBSCRIBE TO HEALTHbeat
VIEW HEALTHbeat ARCHIVES
PRIVACY POLICYVisit our website at: https://www.health.harvard.edu
Email us at: healthbeat@health.harvard.edu

FOLLOW US ON: Facebook logoFacebookX logoTwitterCopyright © 2026 by Harvard University.
Harvard Health Publishing, Gordon Hall, Suite 013, 25 Shattuck Street, Boston, MA 02115, USA

* Please note, we do not provide responses to personal medical concerns, nor can we supply related medical information other than what is available in our print products or website. For specific, personalized medical advice we encourage you to contact your physician.
 

Unknown's avatar

About michelleclarke2015

Life event that changes all: Horse riding accident in Zimbabwe in 1993, a fractured skull et al including bipolar anxiety, chronic fatigue …. co-morbidities (Nietzche 'He who has the reason why can deal with any how' details my health history from 1993 to date). 17th 2017 August operation for breast cancer (no indications just an appointment came from BreastCheck through the Post). Trinity College Dublin Business Economics and Social Studies (but no degree) 1997-2003; UCD 1997/1998 night classes) essays, projects, writings. Trinity Horizon Programme 1997/98 (Centre for Women Studies Trinity College Dublin/St. Patrick's Foundation (Professor McKeon) EU Horizon funded: research study of 15 women (I was one of this group and it became the cornerstone of my journey to now 2017) over 9 mth period diagnosed with depression and their reintegration into society, with special emphasis on work, arts, further education; Notes from time at Trinity Horizon Project 1997/98; Articles written for Irishhealth.com 2003/2004; St Patricks Foundation monthly lecture notes for a specific period in time; Selection of Poetry including poems written by people I know; Quotations 1998-2017; other writings mainly with theme of social justice under the heading Citizen Journalism Ireland. Letters written to friends about life in Zimbabwe; Family history including Michael Comyn KC, my grandfather, my grandmother's family, the O'Donnellan ffrench Blake-Forsters; Moral wrong: An acrimonious divorce but the real injustice was the Catholic Church granting an annulment – you can read it and make your own judgment, I have mine. Topics I have written about include annual Brain Awareness week, Mashonaland Irish Associataion in Zimbabwe, Suicide (a life sentence to those left behind); Nostalgia: Tara Hill, Co. Meath.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a comment